As previously announced, Vivesto AB (“Vivesto” or the “Company”) has applied for delisting of the Company’s shares from Frankfurt Stock Exchange (“FSE”). FSE has now resolved to delist Vivesto’s shares from FSE with effect as of 15 September 2023.
In 2017 Vivesto applied for a delisting of its shares from the FSE, but the application was rejected by the FSE. The FSE’s decision was challenged by Vivesto, and the Company has taken actions in order to achieve a delisting.
The FSE has now resolved to delist Vivesto’s shares from FSE effective as of 15 September 2023, based on non-compliance with listing obligations.
The delisting from the FSE will not affect the listing of the Company’s shares on Nasdaq Stockholm.
“We welcome Frankfurt Stock Exchange’s decision. We have for a long time wished to be delisted from the Frankfurt Stock Exchange to reduce cost and administration. Our main listing on Nasdaq Stockholm provides an efficient exchange for our share and we do not see a need for a secondary listing in this point of time. Also, the practical implication of the decision is limited, since the trade in our share on Frankfurt Stock Exchange has been suspended for many years now,” said Erik Kinnman, CEO of Vivesto.
For further information:
Erik Kinnman, Chief Executive Officer
Phone: +46 18-50 54 40
E-mail: IR@vivesto.com
About Vivesto AB
Vivesto is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a portfolio of projects with the potential of offering cancer patients with unmet medical needs new treatment alternatives. Vivesto has a track-record of developing drugs from the preclinical stage, through clinical development to regulatory approval. Vivesto’s most advanced program Apealea® (paclitaxel micellar) has been granted market approval in the EU as a treatment for adult patients suffering from the first relapse of platinum sensitive epithelial ovarian cancer, or primary peritoneal cancer or fallopian tube cancer. Other clinical development programs include Cantrixil for late-stage ovarian cancer, and Docetaxel micellar, in development for advanced prostate cancer. Moreover, the company is developing Paccal Vet (paclitaxel micellar) for malignant melanoma and hemangiosarcoma in dogs. Vivesto has developed proprietary drug delivery technologies designed to improve solubility of various active pharmaceutical ingredients.
Vivesto’s shares are traded on Nasdaq Stockholm (ticker: VIVE). Visit www.vivesto.com for more information about Vivesto.